Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhanced Post-Licensure Safety Surveillance Study of the Recombinant Acellular Pertussis Vaccine (aP), VacPertagen, in Thailand

NCT07400120 is registered in ClinicalTrials.gov with BioNet-Asia Co., Ltd. as lead sponsor.

NCT NCT07400120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07400120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhanced Post-Licensure Safety Surveillance Study of the Recombinant Acellular Pertussis Vaccine (aP), VacPertagen, in Thailand
Lead sponsor
BioNet-Asia Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
July 16, 2018
Completion date
February 21, 2023
Enrollment
5,414 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pertussis (whooping cough)